Website: https://ambrosiabiosciences.com/
Type of Company: Life Sciences
Company Status: Active
Business: Ambrosia Biosciences is a pharmaceutical company developing a best-in-class orally available, small molecule drug targeting GLP-1 and incretin biology, that is safe, effective, affordable, and globally accessible.
Outcome:
Co-investors: BVF
Boulder, CO – December 10th, 2024 – Ambrosia Biosciences Inc. (“Ambrosia”), today announced the successful second closing of its Series A financing. This closing was led by Merck, known as MSD outside the United States and Canada, with additional participation from existing investors BVF Partners and Boulder Ventures. This additional capital brings Ambrosia’s total Series A financing to $25MM.
Boulder, CO – August 20, 2024 – Ambrosia Biosciences Inc. (“Ambrosia” or “the Company”), today announced the successful first closing of its Series A financing. The financing totaled $16 Million and was led by BVF Partners and Boulder Ventures. Ambrosia’s financing will be used to scale up its drug discovery programs and laboratory operations in Boulder, CO.
